Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity

Part of paid clinical trials in Iowa City, Iowa.

Sponsor
Philip Polgreen
Study ID
NCT05474430
Status
Recruiting
Apply to this trial

Conditions

  • Carrier State
  • Respiratory Infections

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Study Details

A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays. An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19. The participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.

Key Dates

Start date
Dec 20, 2021
Status verified
Jan 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
160 participants (estimated)

Arms

  • Arm: Cystic Fibrosis Carrier Group
    Participants have been identified as Cystic Fibrosis Carriers via previous genetic testing.
  • Arm: Control Group
    Participants have been identified as not being Cystic Fibrosis Carriers via previous genetic testing.

Primary Outcome Measure

Comparison of Chloride Transport Values [ Time Frame: At baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Iowa Hospitals and ClinicsIowa CityIowa52242
Shelby L Francis, PhD
[email protected]
319-678-8037

Find similar trials in Iowa City, IA

By research site
University of Iowa Hospitals and Clinics· Iowa City, IA

Related Studies